Reliable measurement of disease progression and the effect of therapeutic interventions in Duchenne muscular dystrophy (DMD) require clinically meaningful and scientifically sound rating scales. Therefore, we need robust evidence to support such tools. In this June 2011 podcast, Editor in Chief Dr Peter Baxter talks to Anna Mayhew (Institute of Human Genetics, International Centre for Life, Newcastle University, Newcastle upon Tyne, UK) and Mike Horton (Psychometric Laboratory for Health Sciences, Leeds, UK) about the following article: ‘Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy’ by Anna Mayhew, Stefan Cano, Elaine Scott, Michelle Eagle, Kate Bushby, Francesco Muntoni, On Behalf Of The North Star Clinical Network For Paediatric Neuromuscular Disease.

Read the paper here: http://onlinelibrary.wiley.com/doi/10.1111/j.1469-8749.2011.03939.x/abstract

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Developmental Medicine and Child Neurology. Innehållet i podden är skapat av Developmental Medicine and Child Neurology och inte av, eller tillsammans med, Poddtoppen.